Evidence map›Paper›PMID 33975274›Full record

ArticleBiomaterials2021

Development of novel nanofibers targeted to smoke-injured lungs.

Alexandra I Mercel, Kathleen Marulanda, David C Gillis, Kui Sun, Tristan D Clemons, Smaranda Willcox, Jack Griffith, Erica B Peters, Mark R Karver, Nick D Tsihlis and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Alexandra I MercelDepartment of Surgery, University of North Carolina, Chapel Hill, NC, 27599, USA.
Kathleen MarulandaDepartment of Surgery, University of North Carolina, Chapel Hill, NC, 27599, USA.
David C GillisDepartment of Surgery, University of North Carolina, Chapel Hill, NC, 27599, USA.
Kui SunDepartment of Surgery, University of North Carolina, Chapel Hill, NC, 27599, USA.
Tristan D ClemonsSimpson Querrey Institute, Northwestern University, Chicago, IL, 60611, USA; Department of Chemistry, Northwestern University, Evanston, IL, 60208, USA.
Smaranda WillcoxDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, 27599, USA.
Jack GriffithDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, 27599, USA.
Erica B PetersDepartment of Surgery, University of North Carolina, Chapel Hill, NC, 27599, USA.
Mark R KarverSimpson Querrey Institute, Northwestern University, Chicago, IL, 60611, USA.
Nick D TsihlisDepartment of Surgery, University of North Carolina, Chapel Hill, NC, 27599, USA.
Rob MaileDepartment of Surgery, University of North Carolina, Chapel Hill, NC, 27599, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, 27599, USA; Curriculum of Toxicology and Environmental Medicine, University of North Carolina, Chapel Hill, NC, 27599, USA.
Samuel I StuppSimpson Querrey Institute, Northwestern University, Chicago, IL, 60611, USA; Department of Chemistry, Northwestern University, Evanston, IL, 60208, USA; Department of Materials Science & Engineering, Northwestern University, Evanston, IL, 60208, USA; Department of Medicine, Northwestern University, Chicago, IL, 60611, USA; Department of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.
Melina R KibbeDepartment of Surgery, University of North Carolina, Chapel Hill, NC, 27599, USA; Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC, 27599, USA. Electronic address: melina_kibbe@med.unc.edu.
University of North Carolina at Chapel Hill · USNorthwestern University · US

Funding

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
Novel Vehicles for Targeted Cardiovascular RepairR01HL116577 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KIBBE, MELINA RAE, STUPP, SAMUEL I · 2013 to 2016
$4.3M
TRAUMA RESEARCH FELLOWSHIPT32GM008450 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bruce A Cairns, Anthony G Charles · 1992 to 2026
$3.8M
R-loops at the telomere as a toxic source of genomic instabilityR01ES031635 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GRIFFITH, JACK D · 2020 to 2024
$1.7M
Role of extraceullar vesicles in directing immunometabolic homeostasis after burn injuryR01GM131124 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAIRNS, BRUCE A, MAILE, ROBERT · 2019 to 2022
$1.5M
NHLBI NIH HHS R01 HL116577NIEHS NIH HHS R01 ES031635NIGMS NIH HHS R01 GM131124NIGMS NIH HHS T32 GM008450NIGMS NIH HHS T32 GM086330
6 · The paper itself

Abstract

Smoke inhalation injury is associated with significant mortality and current therapies remain supportive. The purpose of our study was to identify proteins upregulated in the lung after smoke inhalation injury and develop peptide amphiphile nanofibers that target these proteins. We hypothesize that nanofibers targeted to angiotensin-converting enzyme or receptor for advanced glycation end products will localize to smoke-injured lungs.

methodsFive targeting sequences were incorporated into peptide amphiphile monomers methodically to optimize nanofiber formation. Nanofiber formation was assessed by conventional transmission electron microscopy. Rats received 8 min of wood smoke. Levels of angiotensin-converting enzyme and receptor for advanced glycation end products were evaluated by immunofluorescence. Rats received the targeted nanofiber 23 h after injury via tail vein injection. Nanofiber localization was determined by fluorescence quantification.

resultsPeptide amphiphile purity (>95%) and nanofiber formation were confirmed. Target proteins were increased in smoke inhalation versus sham (p < 0.001). After smoke inhalation and injection of targeted nanofibers, we found a 10-fold increase in angiotensin-converting enzyme-targeted nanofiber localization to lung (p < 0.001) versus sham with minimal localization of non-targeted nanofiber (p < 0.001).

conclusionsWe synthesized, characterized, and evaluated systemically delivered targeted nanofibers that localized to the site of smoke inhalation injury in vivo. Angiotensin-converting enzyme-targeted nanofibers serve as the foundation for developing a novel nanotherapeutic that treats smoke inhalation lung injury.

Indexed as

NanofibersSmoke Inhalation InjuryAnimalsLungPeptidesRatsSmokePeptidesSmokeAnimal ModelBurnNanotechnologyPeptide amphiphilePulmonary

Identifiers

PMID33975274
PMCPMC8184637
OpenAlexW3158473492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.